VTRS News and Press, Viatris Inc. From 01/07/24

2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...

2024-01-03 07:00:00 ET Summary WisdomTree U.S. MidCap Dividend Fund ETF holds over 300 stocks weighted based on paid dividends, which favors larger companies among mid-caps. It is well-diversified across holdings but quite heavy in financials. The DON ETF is cheaper than the S...

2023-12-29 11:05:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-27 13:33:38 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals Inc. (REGN) American Society of Hematology 2023 Investor Conference - (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 35th Annual Healthcare Conference (Transcript) R...

2023-12-27 07:00:02 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for VTRS on December 27, 2023 07:42AM ET. The previous analyst recommendation was Equal-Weight. VTRS was trading at $10.71 at issue of the analyst recommendation. The overall analyst consens...

Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference PR Newswire PITTSBURGH , Dec. 21, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the 42 nd Annual J.P. ...

Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer Viatris Continues its Preparations for Phase 2 of its Strate...

2023-12-15 16:15:56 ET More on Viatris Viatris Stock Is Dirt Cheap And Worth Buying Viatris: It Is Always Cheap, Yet It Is Always Declining Viatris Inc. 2023 Q3 - Results - Earnings Call Presentation Viatris GAAP EPS of $0.27 misses by $0.07, revenue of $3.94...

Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders PR Newswire Board of Directors Elects Melina Higgins New Chair PITTSBURGH , Dec. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS...

2023-12-14 14:26:24 ET More on AbbVie, AstraZeneca, etc. GSK - Greenshoots In The Horizon AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Is Feeling The Weight Of The Market In 2023 AbbVie, Amgen among firms targeted for latest Medi...